Invest
Should you cash in on the ‘silver economy’ in 2016?
In these volatile times, investors should not overlook global pharmaceutical companies that are benefiting from ageing demographics.
Should you cash in on the ‘silver economy’ in 2016?
In these volatile times, investors should not overlook global pharmaceutical companies that are benefiting from ageing demographics.
Global pharmaceuticals are part of a mega trend that is not sensitive to the global economy or the slowdown in China.
Regulators are approving new drugs at record rates as global pharmaceutical companies respond to the effect of population ageing on healthcare systems.
In 2014, the US Food and Drug Administration approved 50 new drugs composed from 30 new molecular entities and 20 new biological ones, one of the highest numbers of approvals in 20 years.
A recent example of the potential of these new breakthrough drugs is in the treatment of hepatitis C, where a cure has been found.
Nasdaq-listed US biotechnology company Gilead Sciences has developed drugs that are leading the way in all-oral treatments in the fast-growing hepatitis C market.
The company’s two key hepatitis C drugs each generated revenue exceeding $US2 billion within three months of launch, and its first HCV drug generated sales of more than $US10 billion after the first 12 months.
The HCV affects an estimated 3.2 million people in the US and 150-180 million worldwide, and can lead to a number of serious liver complications and death.
The effect of population ageing – also referred to as the silver economy or silver tsunami – is an international phenomenon. In 1950, just eight per cent of the world's population was aged 60 or over.
By 2005 that proportion had risen to 10 per cent and it is expected to more than double over the next 40 years, reaching 22 per cent in 2050.
Globally, the number of people aged 60 and over will nearly triple in size, increasing from 894 million in 2010 to 2.43 billion in 2050.
This ageing population will have a major impact on global healthcare systems. According to Deloitte, it will lead to huge increases in chronic diseases such as heart disease, stroke, cancer, chronic respiratory diseases, diabetes and mental illness.
These diseases are the leading global cause of mortality, representing 63 per cent of all deaths, and can be attributed to the ageing population, more sedentary lifestyles, diet changes and rising obesity levels, as well as improved diagnostics.
In response to this trend, regulators are approving new drugs at record rates, while the review times for new drugs that are saving lives are at historically short levels.
This trend is providing a significant boost for the pharmaceutical sector, where the pipeline of drugs is generating a strong tailwind leading to billions of dollars in revenue.
While Australians can invest in some excellent local healthcare companies, there are limitations.
For instance, these tend to be either single or narrow product device companies, which can place them at a higher risk from product recalls.
Some companies are principally connected to the Australian healthcare sector, such as radiology, pathology and hospital-based companies, exposing them to risks from changing funding structures and regulations.
By diversifying their domestic portfolios into areas which are not available in Australia, such as oncology, diabetes and orthopaedics, investors can benefit from the growing impact of the silver economy on healthcare systems.
Monik Kotecha, chief investment officer, Insync
Cash
RBA makes first cash rate call for 2022
The RBA has announced its first rate decision for 2022. ...Read more
Cash
Cash remains king for many Australians
Demand for banknotes remains high despite a decline in cash transactions. ...Read more
Cash
Interest rates to rise next year?
Commonwealth Bank has seconded Westpac’s predictions, forecasting that interest rates will rise well ahead of the RBA’s 2024 timeline. ...Read more
Cash
RBA makes latest official cash rate call
The Reserve Bank of Australia has made its May call on the official cash rate, with the economy said to be a long way from the conditions needed to precede a rate rise. ...Read more
Cash
RBA puts chatter of an earlier rate hike to rest
The Reserve Bank of Australia has put to rest chatter among investors that conditions for a higher cash rate could be met as early as next year, reaffirming its stance that the rate is “very likely...Read more
Cash
Australia tipped to go cashless by 2024
Australia is forecast to effectively go cashless in just three years, with three in 10 Aussies admitting that “going cashless would be great for the country”. ...Read more
Cash
Tips to finding a middle ground between equities and term deposits
With record-low interest rates and a volatile sharemarket, mature Australians looking to protect their assets while maintaining their income are being driven to fixed-income products, an industry expe...Read more
Cash
What’s next for paper money?
How many times in the past week have you actually had to pull out your wallet to pay for something? And out of those times, did you actually go to use cash? ...Read more
Wrapping up an eventful 2021
Listen now
What Omicron means for property, and are units right for first-time buyers? What is equity crowdfunding? Are industry super funds tapping into member funds to save their skins?
Listen now
Will housing affordability improve in 2022? Will buy now, pay later become the norm? Why are Aussies staying in failing super products?
Listen now
Who really benefits from crypto ETFs? How will the RBA respond to rising inflation? Could a mandate help address unpaid super?
Listen now
Cash
RBA makes first cash rate call for 2022
The RBA has announced its first rate decision for 2022. ...Read more
Cash
Cash remains king for many Australians
Demand for banknotes remains high despite a decline in cash transactions. ...Read more
Cash
Interest rates to rise next year?
Commonwealth Bank has seconded Westpac’s predictions, forecasting that interest rates will rise well ahead of the RBA’s 2024 timeline. ...Read more
Cash
RBA makes latest official cash rate call
The Reserve Bank of Australia has made its May call on the official cash rate, with the economy said to be a long way from the conditions needed to precede a rate rise. ...Read more
Cash
RBA puts chatter of an earlier rate hike to rest
The Reserve Bank of Australia has put to rest chatter among investors that conditions for a higher cash rate could be met as early as next year, reaffirming its stance that the rate is “very likely...Read more
Cash
Australia tipped to go cashless by 2024
Australia is forecast to effectively go cashless in just three years, with three in 10 Aussies admitting that “going cashless would be great for the country”. ...Read more
Cash
Tips to finding a middle ground between equities and term deposits
With record-low interest rates and a volatile sharemarket, mature Australians looking to protect their assets while maintaining their income are being driven to fixed-income products, an industry expe...Read more
Cash
What’s next for paper money?
How many times in the past week have you actually had to pull out your wallet to pay for something? And out of those times, did you actually go to use cash? ...Read more
